Outreach and Connection to Care for Chronic Kidney Disease in a Workplace Wellness Setting: A Cost-Effectiveness Analysis

被引:0
|
作者
Li, Yonghong [1 ]
Devlin, James J. [1 ]
机构
[1] Quest Diagnost, 33608 Ortega Highway, San Juan Capistrano, CA 92675 USA
关键词
chronic kidney disease; cost-effectiveness analysis; Markov modeling; CARDIOVASCULAR OUTCOMES; NEPHROPATHY; INHIBITORS;
D O I
10.1089/pop.2019.0206
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Because chronic kidney disease (CKD) is underdiagnosed, many patients do not receive care that could slow or prevent progression. Potential CKD patients can be identified during employee wellness events and referred into care by a CKD outreach program. This study assessed the health and economic benefits associated with a CKD outreach program. A model-based cost-effectiveness analysis was conducted for a cohort of patients at risk for CKD under 2 scenarios: wellness events with a CKD outreach program and wellness events without outreach. The outreach program identified potential CKD patients based on estimated glomerular filtration rates. Health outcomes and total cost to payers were estimated with Markov models using 1-year cycles. Because outreach could be offered to either patients with diabetes or to all potential CKD patients, these groups were modeled separately. The authors assumed 40% percent of potential CKD patients accepted the invitation to participate in the CKD outreach program. Model parameters were taken from peer-reviewed literature. The study was conducted from the perspective of self-insured employers over a 5-year time horizon. The study found that the CKD outreach program resulted in a gain of 2.3 quality-adjusted life-years and saved $500,211 when 1000 potential CKD patients with diabetes were invited. When potential CKD patients were invited without regard for diabetes status, 0.8 quality-adjusted life-years were gained at a cost savings of $34,161. The authors concluded that CKD outreach programs can improve health outcomes for patients with CKD and save costs for payers.
引用
收藏
页码:487 / 494
页数:8
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN THE TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE IN FRANCE
    Supiot, R.
    Tardu, J.
    Virely, N.
    Sivignon, M.
    Chollet, J.
    Uster, A.
    Levy, P.
    Massy, Z.
    VALUE IN HEALTH, 2024, 27 (12) : S365 - S365
  • [32] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS AFFECTED BY CHRONIC KIDNEY DISEASE IN ITALY
    Di Costanzo, A.
    Uster, A.
    Vassallo, C.
    Fiorentino, F.
    VALUE IN HEALTH, 2023, 26 (12) : S73 - S73
  • [33] Hyaluronic acid treatment versus standard of care in chronic wounds in a German setting: Cost-effectiveness analysis
    Blunck, Dominik
    Schoeffski, Oliver
    HEALTH SCIENCE REPORTS, 2023, 6 (01)
  • [34] Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom
    Ramos, Mafalda
    Gerlier, Laetitia
    Uster, Anastasia
    Muttram, Louise
    Frankel, Andrew H.
    Lamotte, Mark
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 777 - 785
  • [35] Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study
    Lin, Eugene
    Chertow, Glenn M.
    Yan, Brandon
    Malcolm, Elizabeth
    Goldhaber-Fiebert, Jeremy D.
    PLOS MEDICINE, 2018, 15 (03)
  • [36] COST-EFFECTIVENESS ANALYSIS OF USING KETOANALOGUES OF ESSENTIAL AMINOACIDS IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN KAZAKHSTAN
    Avdeyev, A.
    Gulyaev, A.
    Akhmedullin, R.
    VALUE IN HEALTH, 2023, 26 (12) : S73 - S73
  • [37] Cost-Effectiveness of Screening and Optimal Management for Diabetes, Hypertension, and Chronic Kidney Disease: A Modeled Analysis
    Howard, Kirsten
    White, Sarah
    Salkeld, Glenn
    McDonald, Stephen
    Craig, Jonathan C.
    Chadban, Steven
    Cass, Alan
    VALUE IN HEALTH, 2010, 13 (02) : 196 - 208
  • [38] COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
    Sanchez-Alvarez, Emilio E.
    Poveda, J. L.
    Sanchez-Villanueva, R.
    Ramirez, de Arellano Serna A.
    Olga, R.
    De, La Paz Canizares I.
    Hernaez Colque, M.
    VALUE IN HEALTH, 2024, 27 (12) : S126 - S126
  • [39] When to Start Population-Wide Screening for Chronic Kidney Disease A Cost-Effectiveness Analysis
    Cusick, Marika M.
    Tisdale, Rebecca L.
    Chertow, Glenn M.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    JAMA HEALTH FORUM, 2024, 5 (11):
  • [40] WILL COST-EFFECTIVENESS ANALYSIS WORSEN THE COST-EFFECTIVENESS OF HEALTH-CARE
    HIMMELSTEIN, DU
    WOOLHANDLER, S
    BOR, DH
    INTERNATIONAL JOURNAL OF HEALTH SERVICES, 1988, 18 (01): : 1 - 9